BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 37173373)

  • 1. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
    Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
    Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of multi-omics data reveals a pseudouridine-related lncRNA signature for prediction of glioma prognosis and chemoradiotherapy sensitivity.
    Yang Y; Wang F; Teng H; Zhang C; Zhang Y; Chen P; Li Q; Kan X; Chen Z; Wang Z; Yu Y
    Comput Biol Med; 2023 Nov; 166():107428. PubMed ID: 37748218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
    He Y; Ye Y; Tian W; Qiu H
    Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune-related lncRNAs signature and radiomics signature predict the prognosis and immune microenvironment of glioblastoma multiforme.
    Luan J; Zhang D; Liu B; Yang A; Lv K; Hu P; Yu H; Shmuel A; Zhang C; Ma G
    J Transl Med; 2024 Jan; 22(1):107. PubMed ID: 38279111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
    Zhang M; Wang X; Chen X; Zhang Q; Hong J
    Front Genet; 2020; 11():363. PubMed ID: 32351547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma.
    Chen Z; Zhang W; Yan Z; Zhang M
    Cancer Med; 2023 Jan; 12(1):760-788. PubMed ID: 35668574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel prognostic related lncRNA signature associated with amino acid metabolism in glioma.
    Lei Q; Yuan B; Liu K; Peng L; Xia Z
    Front Immunol; 2023; 14():1014378. PubMed ID: 37114036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
    Zhao J; Wang L; Wei B
    Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
    Zhang Z; Wang J; Han W; Zhao L
    BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
    Zhang C; Liu H; Xu P; Tan Y; Xu Y; Wang L; Liu B; Chen Q; Tian D
    BMC Cancer; 2021 Mar; 21(1):251. PubMed ID: 33750353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
    Zhang M; Cheng Y; Xue Z; Sun Q; Zhang J
    BMC Cancer; 2021 Dec; 21(1):1311. PubMed ID: 34876094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prognostic Microenvironment-Related Immune Signature
    Qiu H; Li Y; Cheng S; Li J; He C; Li J
    Front Oncol; 2020; 10():580263. PubMed ID: 33425732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
    Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
    Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine Learning-Based Integration Develops a Pyroptosis-Related lncRNA Model to Enhance the Predicted Value of Low-Grade Glioma Patients.
    Wu J; Lu L; Wang C; Jiang F
    J Oncol; 2022; 2022():8164756. PubMed ID: 35646114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
    Xu S; Wang Z; Ye J; Mei S; Zhang J
    Front Oncol; 2021; 11():729103. PubMed ID: 34568059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mitochondrial function-related LncRNA signature predicts prognosis and immune microenvironment for breast cancer.
    Wang Y; Gao S; Xu Y; Tang Z; Liu S
    Sci Rep; 2023 Mar; 13(1):3918. PubMed ID: 36890266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TGF-β signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response.
    Duan WW; Yang LT; Liu J; Dai ZY; Wang ZY; Zhang H; Zhang X; Liang XS; Luo P; Zhang J; Liu ZQ; Zhang N; Mo HY; Qu CR; Xia ZW; Cheng Q
    CNS Neurosci Ther; 2024 Apr; 30(4):e14489. PubMed ID: 37850692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.